Market Research Report
Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016
|Published by||Visiongain Ltd||Product code||253510|
|Published||Content info||174 Pages
Delivery time: 1-2 business days
|Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016|
|Published: June 13, 2016||Content info: 174 Pages||
MEDICAL DEVICE LEADER SERIES: TOP NEEDLE-FREE INJECTION DEVICE DEVELOPERS, MANUFACTURERS AND MARKETERS IN 2016
Market Analysis Including Antares Pharma, PharmaJet, Mylan and Other Firms in North America, Europe, Israel and Asia Pacific, Covering Jet Injectors, Transdermal Patches, Microneedles, Pen Injectors and Other Drug Delivery Systems.
What does the future hold for producers of needle-free injection (NFI) products? Visiongain's updated, expanded report shows you data to 2026 for that industry and market. There you find analysis, trends, opportunities, prospects and revenue forecasting. Don't miss out.
Our new study analyses 28 leading developers and producers of those medical devices. NFI drug delivery holds great potential from 2016 for the therapeutic and commercial advancement of biologics and vaccines. Discover what that progress means and how you can benefit your work and influence.
So read on, please, to scan that industry's leading participants and see what its future market could be worth.
With our study you examine the industry for needleless injection and needle-free syringes - insulin injectors and other systems. Explore that industry's progress. See the potential for novel and improved subcutaneous, intradermal, intramuscular and intravenous drug delivery.
That market advances fast. In our report you assess product ranges, historical data, R&D, sales prediction and financial results. There you gain quantitative and qualitative analyses. In our 173 page report you find 74 tables, 9 charts and an interview with a prominent company.
In our analysis you see how developers overcome problems with parenteral drug application, especially benefiting the use of biological drugs. You also discover potential revenues.
The following sections explain how our new investigation can benefit your work.
First our study gives you financial data and discussions for prominent North American NFI developers and manufacturers:
Discover what the present and future hold for leading companies. Also see revenue predictions to 2026 for the overall world industry for needle-free injection devices.
Also hear about developments and prospects of firms in other countries.
Next our report analyses European-based specialists in that drug delivery:
Many commercial opportunities exist, with expanding revenues possible from 2016 to 2026. Explore companies well placed to succeed. That way you see how organisations gain advantages, develop technologies and increase revenues.
How do companies in India, China, South Korea, Singapore, Israel and Australia contribute? Our report shows activities, results and outlooks of these organisations:
With our survey you discover progress, potentials and R&D across the world, assessing what is possible from 2016. Stay ahead in knowledge to help your work.
Our study explains issues affecting that industry and market from 2016, including these influences:
There you explore political, economic, social and technological questions, investigating outlooks for business. Examine what stimulates and restrains that industry and market.
Our study forecasts that overall worldwide sales of needle-free injection devices will reach $1.98 billion in 2020, with strong sales growth to 2026. With that analysis you explore how those companies, progress, compete and succeed. Avoid missing out on data.
You also read opinions from a company we interviewed. See what that industry's present and future hold, assessing opportunities for companies to contribute, expand and benefit.
Our report gives the following knowledge to benefit your research, analyses, plans, decisions and presentations:
That investigation, by visiongain's in-house team in the UK, has the purpose of helping everyone interested in the future of needle-free injections and related drugs, instruments, containers and accessories. Discover analysis leading organisations depend on.
With our research and analysis you are less likely to fall behind in knowledge or miss opportunity. There see how you could save time and effort. That way you could benefit your plans, decisions and presentations, helping you gain advantages and recognition.
Our new research is for everyone analysing drug delivery and pharmaceutical R&D. For leading companies and technologies you explore trends, progress and opportunities. So avoid missing out - please get our new report here now.
visiongain is a trading partner with the US Federal Government.